Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Completed 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Genitourinary 3Thoracic 1Sarcoma 1Gynecologic 1Breast 1

Conditions

Ovarian Neoplasms 6Breast Neoplasms 4Sarcoma 2Prostatic Neoplasms 2Fallopian Tube Neoplasms 2Carcinoma, Non-Small-Cell Lung 2Uterine Cervical Neoplasms 1Triple Negative Breast Neoplasms 1Pancreatic Neoplasms 1Neoplasm Metastasis 1Melanoma 1Lung Neoplasms 1Carcinoma, Transitional Cell 1Carcinoma, Renal Cell 1Carcinoma, Ovarian Epithelial 1

Interventions

pembrolizumab 24Nivolumab 15Magnetic Resonance Spectroscopy 7Ipilimumab 6avelumab 5atezolizumab 5Specimen Handling 5Docetaxel 4lenvatinib 3durvalumab 3Paclitaxel 3Cyclophosphamide 3Carboplatin 3fludarabine 2cabozantinib 2aldesleukin 2Interleukin-2 2Fluorodeoxyglucose F18 2FAPI-46 2zanidatamab 1veliparib 1tislelizumab 1spartalizumab 1soluble LAG-3 protein, human 1sargramostim 1sacituzumab govitecan 1rucaparib 1regorafenib 1poly ICLC 1olaparib 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Carcinoma, Transitional Cell × eribulin × Gynecologic × Clear all
NCT02014337 2018-01-17

Mifepristone and Eribulin in Patients With Metastatic Triple Negative Breast Cancer or Other Specified Solid Tumors

Corcept Therapeutics

Phase 1 Completed
37 enrolled
BreastGenitourinaryGynecologicSarcomaThoracic

Breast Neoplasms, Carcinoma, Non-Small-Cell Lung, Carcinoma, Transitional Cell, Ovarian Neoplasms, Prostatic Neoplasms, Sarcoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡